Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors

NCT05053971 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05053971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05053971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 16, 2022
Completion date
July 1, 2027
Enrollment
49 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, locally advanced pancreatic carcinoma, metastatic pancreatic carcinoma, refractory malignant solid neoplasm, refractory pancreatic carcinoma, stage ii pancreatic cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8, unresectable pancreatic carcinoma